Continuous infusion of factor VIII for surgery and major bleeding

Area of Science:

• Hematology
• Pharmacokinetics
• Clinical Trials

Background:

• Hemophilia A is a bleeding disorder requiring factor VIII replacement therapy.
• Traditional bolus infusions can lead to fluctuating factor VIII levels.
• Continuous infusion offers a potential alternative for maintaining therapeutic factor VIII concentrations.

Purpose of the Study:

• To assess the safety, efficacy, and economic viability of continuous infusion Monoclate P in hemophilia A patients.
• To determine pharmacokinetic parameters of factor VIII during continuous infusion.
• To compare the cost-effectiveness of continuous infusion versus bolus therapy.

Main Methods:

• A clinical trial involving 24 hemophilia A patients undergoing surgery or experiencing severe bleeding.
• Continuous infusion of Monoclate P with dose adjustments to maintain target factor VIII levels (100 IU/dl then 80 IU/dl).
• Pharmacokinetic analysis using a single-compartment model to determine clearance, elimination rates, and half-life.
• Economic comparison with theoretical bolus therapy dosages.

Main Results:

• No hemorrhagic episodes were observed, indicating safety and efficacy.
• Continuous infusion provided convenient, steady-state factor VIII levels.
• Median factor VIII half-life was 9.9 hours; clearance and elimination rates appeared to decrease over time.
• Potential cost savings of up to 75% on the first postoperative day, averaging 35% over therapy.

Conclusions:

• Continuous infusion of Monoclate P is a safe and effective treatment for hemophilia A.
• This method ensures stable factor VIII levels and offers significant economic advantages over bolus therapy.
• The pharmacokinetic profile suggests potential for optimized dosing strategies in continuous infusion therapy.